Kagan, Valerian E
- University of Pittsburgh · Public Health (NIH department code)
- Wistar Institute (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #7,931
- Rising Star
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2001 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Public Health
NIH Funding · FY2023
Linked Award Amount
$1.2M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#7,931
By linked amount among FY2023 PIs
Earliest Year Loaded
2001
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Kagan, Valerian E as a PI. Multi-PI records show the full award amount for context.
- 5R01CA266342-02R01Contact PITherapeutic targeting MDSC-mediated immune suppression in cancer$682.6Kaward amount
- 5R01AI145406-04R01Contact PIProtein-Oxidized Phospholipid Interactions Determine Epithelial Cell Fate and Asthma ControlUniversity of Pittsburgh · Public Health (NIH department code)$535.1Kaward amount
Award organizations
Organizations that administered FY2023 awards listing Kagan, Valerian E as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2001First NIH AwardWistar Institute
- 2002$500K Cumulative Funding
- 2002Entered Top 50% NationallyRanked #6702
- 2002Multi-Institutional ResearchAwards at 2 institutions
- 2003$1M Cumulative Funding
- 2005$2M Cumulative Funding
- 2005R01 Grant Holder
- 2021$5M Cumulative Funding
- 2022Entered Top 25% NationallyRanked #4871